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Introduction
Idiopathic intracranial hypertension (IIH) is a chronic and disabling condition characterized by elevated 
intracranial pressure (ICP) (1). Patients have reduced quality of  life due to chronic headaches and pap-
illedema-induced visual loss (permanent in 25% of  patients) (2, 3). Predominantly occurring in areas of  
socioeconomic deprivation, IIH incidence is rising rapidly in line with the global epidemic of  obesity (2 per 
100,000 in 2002 to 5 per 100,000 in 2016), driving escalating health care costs (predicted at ≤450 million 
dollars per year by 2030) (4). IIH is overwhelmingly a disease of  obese women of  reproductive age (5, 6), 
and endocrine disturbances have been hypothesized to play a pathogenic role (7, 8). However, IIH etiology 
remains unexplained (3); identifying the cause of  IIH was determined as the most important research ques-
tion by IIH patients in a recent research priority–setting exercise (3).
IIH shares phenotypic characteristics with polycystic ovary syndrome (PCOS), in which androgen 
excess is a defining feature (9). Studies have suggested that the prevalence of  PCOS is increased in IIH, 
as compared with the background population (10, 11), and case reports have described the onset of  IIH 
in patients receiving androgen treatment when undergoing female-to-male sex reassignment (12). Hyper-
androgenism has been identified in younger onset cases of  IIH (13). However, the androgen phenotype of  
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potential causal driver and therapeutic target in IIH.
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women with IIH has not been studied in detail or compared with the androgen profile in PCOS. Androgen 
receptors are noted in the choroid plexus (14, 15), but there are no mechanistic studies examining their 
potential impact on cerebrospinal fluid (CSF) secretion.
We aimed to delineate the androgen phenotype of  women with active IIH and to explore the potential 
role of  androgens in disease pathogenesis. To this end, we have performed complementary in vivo and ex 
vivo investigations, comprehensively examining the androgen metabolome in serum, urine, and CSF in a 
large cohort of  women with active IIH (papilledema and lumbar puncture pressure >25 cm CSF on the day 
of  sample collection) compared with sex-, age-, and BMI-matched women with PCOS or simple obesity. 
We used state-of-the-art mass spectrometry–based analysis and employed cell models to investigate the 
functional role of  androgens in CSF secretion.
Results
Women with IIH have a distinct androgen excess profile compared with PCOS and simple obesity. Age and BMI 
were not significantly different among the 3 groups comprising women with IIH (n = 70), simple obesity 
(n = 40), and PCOS (n = 60) (Table 1). We measured serum androgens by liquid chromatography–tandem 
mass spectrometry (LC-MS/MS) (Table 1 and Figure 1). Serum concentrations of  the active androgen 
testosterone (Figure 1B) were significantly higher in patients with IIH compared with controls with PCOS 
and simple obesity (all P < 0.001). Conversely, the androgen precursor androstenedione (Figure 1C) was 
significantly lower in IIH than in controls with PCOS (P < 0.001) and obesity (P < 0.05). In keeping with 
previous studies, serum androstenedione was higher in PCOS than in controls with obesity (P < 0.01) and 
IIH (P < 0.001). 11-Oxygenated androgens are adrenal derived and have recently been shown to be the 
major contributor to androgen excess in PCOS (16); therefore, we also determined their concentrations. 
Serum concentrations of  the 11-oxygenated androgen precursors 11OH4 (Figure 1F) and 11KA4 (Figure 
1G) were increased only in PCOS (all P < 0.001) compared with controls with IIH and obesity.
Systemic steroid metabolism in 24-hour urine samples was profiled using gas chromatography-mass 
spectrometry in the 3 study groups (Table 1 and Figure 1, H and I). The ratios of  An/Et and 5α- 5α-THF/
THF determine net systemic 5α-reductase activity, an important reaction in androgen activation (17), 
which was significantly increased in IIH as compared with controls with PCOS and obesity (P < 0.05).
Active androgens are elevated in CSF from women with IIH compared with controls. We measured CSF 
androgen concentrations in 55 women with IIH, 19 healthy volunteer controls with obesity and no 
known comorbidities, and 31 lean controls (indications for lumbar puncture: headache n = 9, demye-
lination n = 6, cerebrovascular disease n = 3, normal investigations n = 5, other n = 8) (Figure 2, A–D). 
The obese controls were matched for age but had a higher BMI than the cohort with IIH (P = 0.01); lean 
controls were significantly older (P < 0.001) than the IIH patients (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.125348DS1). CSF levels 
of  the active androgen testosterone were significantly higher in IIH patients (P < 0.001, Figure 2A). CSF 
concentrations of  the immediate testosterone precursor androstenedione were significantly higher in IIH 
patients than controls (P < 0.0001, Figure 2B). CSF concentrations of  the androgen precursor DHEA 
were higher in lean compared with obese control patients (P = 0.04) but did not differ significantly 
between other groups, with CSF DHEAS highest in the obese control group and significantly greater in 
both lean and obese controls than in women with IIH (Figure 2, C and D, P < 0.0001). 11-Oxygenated 
androgens were detectable in CSF in both IIH patients and control women but did not differ signifi-
cantly between the 2 groups. Serum androstenedione and testosterone both correlated significantly with 
CSF androstenedione and testosterone (r = 0.31, P = 0.03; and r = 0.32, P = 0.03, respectively). Total 
amounts of  serum and CSF androgens (calculated as the sum of  testosterone, androstenedione, DHEA, 
and DHEAS) were also positively correlated (r = 0.29, P = 0.02).
There were no significant correlations between serum or CSF androgen concentrations and BMI 
or markers of  IIH disease activity (ICP, papilledema, logMAR visual acuity, Humphrey Visual Field 
mean deviation, average and maximal retinal nerve fiber layer thickness measured by Optical Coher-
ence Tomography [OCT], Headache Impact Test-6 [HIT-6], or subjective health status [SF-36 ques-
tionnaire]) (Supplemental Methods).
Human choroid plexus expresses androgen receptor and androgen-activating enzymatic machinery. IIH patho-
genesis is speculated to involve either increased CSF secretion (predominantly at the choroid plexus) or 
reduced CSF-draining pathways (18). We have previously demonstrated that pharmacological reduction 
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of  CSF secretion can reduce ICP (19, 20). To characterize the role androgens could play in CSF secretion 
and potentially IIH pathogenesis, we profiled mRNA expression of  androgen-metabolizing enzymes in 
human female choroid plexus samples (n = 5) (Parkinson’s UK Brain Bank, Imperial College, London, 
United Kingdom). These included 3β-hydroxysteroid dehydrogenase type 2 (HSD3B2), aldoketoreduc-
tase type 1 C3 (AKR1C3), 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3), 5α-reductase type 1 
(SRD5A1), aromatase (CYP19A1), 11β-hydroxylase (CYP11B1), aldoketoreductase type 1 D1 (AKR1D1), 
and the androgen receptor (AR)] (Figure 2, E–L), as well as 5α-reductase type 2 (SRD5A2, not shown), 
comparing expression levels to female human ovary, liver, and adrenal tissues (n = 3). Expression lev-
els of  the steroidogenic enzymes AKR1C3 (activation of  androstenedione to testosterone), 17BHSD3, 
SRD5A1, and AR in the human choroid plexus samples were equivalent to or greater than expression 
levels observed in adrenal and ovarian tissue. Expression of  SRD5A2, HSD3B2, CYP19A1, and AKR1D1 
was negligible or undetectable in all samples. Furthermore, CYP11B1, which catalyzes the conversion of  
the classic androgen precursor androstenedione to 11-hydroxyandrostenedione, was also not expressed 
in human choroid plexus (Figure 2J). This is in keeping with our finding of  normal concentrations of  
11-oxygenated androgens in serum and CSF of  IIH patients. We have previously noted the absence of  
HSD11B2 expression in human choroid plexus (7)
Testosterone increases Na+/K+-ATPase activity in rodent choroid plexus in vitro. Akin to human choroid plexus, rat 
choroid plexus tissue and choroid plexus epithelial cells (Z310 cell line) expressed key steroidogenic enzymes 
and Ar (Figure 3, A–D). To determine whether testosterone could modulate CSF secretion, we used a dynamic 
reporter assay of ATP consumption (Supplemental Methods and Figure 1) in Z310 cells. This assay evaluates 
the drop in ATP/ADP ratio in the presence and absence of ouabain and hence provides a readout of the Na+/
K+-ATPase activity, a validated surrogate measure of CSF secretion (20). Testosterone was found to increase 
the ΔATP/ADP ratio compared with vehicle-treated cells at 15 minutes (Δ0.042 ± 0.07 versus Δ0.018 ± 0.02, P 
< 0.0001) and the area under the curve of the ratio over 15 minutes (0.77 ± 0.59 versus 0.56 ± 0.28, P < 0.01), 
indicating increased Na+/K+-ATPase activity and by implication CSF production (Figure 3, E–G). Expression 
of carbonic anhydrases II and III (Car2 and Car3), which establish the ion gradient to drive CSF secretion, were 
significantly upregulated (both P < 0.05) in testosterone-treated Z310 cells at 48 hours compared with vehi-
cle-treated controls. Levels of Na+/K+-ATPase (Atp1a1) expression did not change. (Figure 3H).
Table 1. Baseline characteristics and biochemical data
Controls (n = 40) PCOS (n = 60) IIH (n = 70)
Age (years) 34 (28–38) 30 (27–35) 34 (28–38)
BMI (kg/m2) 37.3 (35.0–41.1) 38.5 (35.5–43.1) 37.9 (34.9–42.3)
Serum androgens (nmol/l)
T 1.0 (0.5–1.4) 1.2 (0.5–1.5) 1.7 (1.0–2.4)A,B
A4 3.6 (2.7–7.5) 5.7 (4.3–9.1)C 2.4 (1.4–4.4)B,D
DHEA 17.9 (9.7–25.1) 13.3 (8.5–22.6) 9.5 (4.9–18.9)E
DHEAS (μmol/l) 4.1 (3.0–6.4) 6.2 (4.3–8.5) 4.5 (2.5–8.4)
11OHA4 3.4 (2.1–7.4) 30.0 (10.6–42.1)A 2.5 (1.6–3.4)B
11KA4 0.7 (0.3–1.0) 12.1 (6.6–21.2)A 0.4 (0.2–0.7)B
11OHT 0.3 (0.1–0.5) 0.3 (0.2–0.5) 0.2 (0.1–0.45)
11KT 1.7 (0.8–2.2) 2.3 (1.5–3.6)D 2.3 (1.9–3.1)
24–hour urine androgen profiling
5α–THF/THFF 0.9 (0.5–1.3) 0.9 (0.7–1.3) 1.2 (0.8–1.80)D,E
An/Et ratioF 1.3 (0.9–1.8) 1.3 (0.9–1.8) 1.4 (0.9–2.2)
Total androgen metabolites  
(An + Et, μg/24 hours)
2,575 (1,864–4,436) 4,341 (2,508–5,497) 3,332 (1,914–5,847)
Median and interquartile range. 2-way ANOVA with post hoc Tukey’s testing: AP < 0.001 for the comparison of PCOS or IIH versus simple obesity; 
BP < 0.001 for the comparison of PCOS versus IIH; CP < 0.01 and DP < 0.05 for the comparison of PCOS or IIH versus simple obesity; and EP < 0.05. 
FSteroid metabolite ratios indicative of systemic 5α-reductase activity, a major androgen-activating reaction. 5α-THF, 5α-tetrahydrocortisol; 11OHA4, 
11β-hydroxyandrostenedione; 11KA4, 11-ketoandrostenedione; 11OHT, 11β-hydroxytestosterone; 11KT, 11-ketotestosterone; A4, androstenedione; An, 
androsterone; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; Et, etiocholanolone; T, testosterone. 
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Discussion
In the current study, we provide potentially novel insights into potential mechanisms relating to the patho-
genesis of  IIH. We highlight a distinct profile of  androgen excess in women with IIH and demonstrate 
an impact of  androgens on surrogate markers of  CSF secretion in a cell model, providing evidence for a 
pathogenetic link between androgen excess and increased ICP in IIH.
We show that women with IIH have a unique circulating androgen excess signature, with significantly 
higher active testosterone but lower concentrations of  the androgen precursors DHEA and androstene-
dione than in women with PCOS or simple obesity. Previous studies of  androgen metabolism in PCOS 
show complex contributions from both the classic (21) and 11-oxygenated androgen pathways (14). Wom-
en with PCOS have systemic upregulation of  androgen-activating 5α-reductase activity, which converts 
testosterone to potent dihydrotestosterone (17), and androgen activation is enhanced in peripheral tissues, 
Figure 1. Serum and urinary androgen metabolism. (A) Androgen pathways. (B–E) Serum androgen concentrations in obese controls (n = 40), PCOS patients 
(n = 60), and IIH patients (n = 70). (F and G) Serum 11-oxygenated androgens in obese controls (n = 35), PCOS patients (n = 20), and IIH patients (n = 13). (H and 
I) Urinary steroid excretion in obese controls (n = 15), PCOS patients (n = 30), and IIH patients (n = 40). 5α-Reductase activity is indicated by the ratio of 5α-tet-
rahydrocortisol/tetrahydrocortisol (5α-THF/THF), and total androgen metabolite excretion was calculated as the sum of androsterone plus etiocholanolone. 
Data presented as median and interquartile range. *P < 0.05, **P < 0.01, ***P < 0.001; Kruskal-Wallis test. 
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such as adipose (22). 11-Oxygenated C19 androgens are the major circulating androgens in PCOS (16). By 
contrast, we found that 11-oxygenated androgen concentrations in serum and CSF were not increased in 
IIH, indicating that adrenal androgen synthesis is not a major contributor to IIH-related androgen excess.
We measured CSF androgens using a highly sensitive and specific LC-MS/MS method. CSF testos-
terone concentrations were significantly higher in IIH, with relatively low levels of  the inactive androgen 
precursor sulfate ester DHEAS. Interestingly, CSF androstenedione was significantly higher in IIH than 
controls, a different pattern than that observed in serum. CSF testosterone and estradiol have been pre-
viously quantified in women with PCOS using immunoassays (23); however, the absolute levels are not 
Figure 2. CSF androgen metabolism. Lean controls (mixed non-IIH neurological diseases) (n = 31), obese controls (healthy volunteers with obesity) (n = 19), 
and IIH patients (n = 55). (A) Testosterone (T) and (B) androstenedione (A4) were significantly higher in the IIH cohort compared with both control groups 
(P < 0.0001 for both). (C) CSF DHEA levels were higher in lean compared with obese controls but did not differ between controls and women with IIH. (D) 
CSF DHEAS levels were significantly higher in control women with obesity than in both lean controls and women with IIH (P < 0.0001). (E–L) HSD3B2, 
AKR1C3, HSD17B3, SRD5A1, CYP19A1, CYP11B1, AKR1D1, and AR mRNA expression in human choroid plexus (n = 5), ovary (n = 3), liver (n = 3), and adrenal 
(n = 3) tissue. Axes not uniform due to differences in mRNA expression. (A–D) Presented as median and interquartile range. *P < 0.05, ****P < 0.0001; 
Kruskal-Wallis test. (E–L) Presented as mean ± SEM.
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comparable to our data because immunoassays can be hampered by cross-reactivity, decreasing sensitivity 
and specificity compared with LC-MS/MS (24), particularly for quantification of  steroids present in low 
concentrations. Different systemic and target tissue-specific hormone concentrations are a recognized phe-
nomenon, with discrepant systemic and adipose tissue concentrations of  dihydrotestosterone identified in 
PCOS (22). In the context of  IIH, it is possible that high CSF androstenedione concentrations provide a 
pool of  androgen precursors for activation to testosterone by the choroid plexus (Figure 3I). In this study, 
we found expression of  the androgen-activating enzyme AKR1C3 in human choroid plexus, indicating the 
presence of  the enzymatic machinery required for activation of  androstenedione to testosterone. Signifi-
cant aromatization of  androstenedione to estrone, or testosterone to estradiol, within the choroid plexus 
appears unlikely in view of  the low levels of  choroid plexus CYP19A1 expression and the well-recognized 
poor efficiency of  this enzyme in converting androgens to estrogens (25).
Figure 3. Functional effect of testosterone on rodent choroid plexus. (A–D) mRNA expression in female rats normalized to ribosomal 18S; n = 3 biological 
replicates (mean ± SEM). Z310 cells are immortalized choroid plexus epithelial cells. (E–G) Z310 cells incubated with 100 nM testosterone for 2 days 
increased the ΔATP/ADP ratio at 15 minutes and AUC (AU) of the ratio over 15 minutes, indicating increased Na+/K+-ATPase activity, a surrogate measure 
of CSF production (n = 39 cells from 3 pooled coverslips). V, vehicle; F, intensity for cell in particular frame; Fmin, lowest fluorescence intensity at baseline. 
Data presented as mean ± SD in E; box and whisker plots in F and G present data as median and interquartile range, showing minimum and maximum val-
ues. (H) mRNA expression of carbonic anhydrases II and III (Car2 and Car3) and Na+/K+-ATPase (Atp1a1) at 48 hours in testosterone-treated (versus vehicle) 
Z310 cells (n = 3 repeats, mean ± SEM). Mann-Whitney U test used for E–H; *P < 0.05, **P < 0.01, and ****P < 0.0001. (I) Concept figure linking systemic 
and CSF androgen activation and impact on CSF secretion at the choroid plexus.
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CSF is in intimate contact with the choroid plexus; therefore, CSF androgen excess could affect 
choroid plexus function. We have shown that human choroid plexus expresses both the AR and the 
critical steroidogenic machinery for androgen activation, but whether androgens are activated directly 
in the choroid plexus, or reach the choroid plexus after activation in the peripheral tissues, such as adi-
pose, remains unclear. Using Na+/K+-ATPase activity as a surrogate of  CSF secretion, we demonstrated 
that testosterone could drive CSF output in choroid plexus cells. These observations are supported by 
increased mRNA expression of  Car 2 and Car 3 after testosterone exposure, providing evidence for a role 
of  androgens in modulating CSF dynamics in IIH.
A central role for androgens in the pathogenesis of  IIH in women may seem biologically implausible 
when it is considered that IIH is rare in men (5). However, androgens exert sexually dimorphic effects 
on human metabolism (26). Men with hypogonadism develop a similar adverse metabolic phenotype to 
women with androgen excess. In both groups, the risk of  type 2 diabetes, nonalcoholic fatty liver disease, 
and cardiovascular mortality are increased (27, 28). There are a number of  potential explanations for this 
sex-specific difference, including epigenetic modifications to local androgen action or differences in the 
sensitivity or signaling of  the AR in both sexes. IIH may therefore be a distinct manifestation of  these sex-
ually dimorphic observations. Intriguingly, men with IIH are more likely to have symptoms of  androgen 
deficiency, such as erectile dysfunction and reduced libido (29). Additionally, men can develop an IIH-like 
condition (Pseudotumor cerebri) in the setting of  low testosterone attributed to gonadotropin deficiency or 
administration of  androgen deprivation therapy (30).
Our study is limited in that it has not characterized androgen metabolism in a male cohort with IIH. 
This would be of  interest but these studies are challenging because male IIH is very rare, accounting for less 
than 5% of  all IIH cases (5). Additionally, IIH in men is atypical, often caused by secondary factors, and 
may not share a similar etiology to IIH in women (3).
The relationship between testosterone and body weight is of interest. Our studies are limited because we 
cannot exclude the possibility that androgen excess has driven weight gain in the obese participants. Androgen 
excess can increase visceral adiposity; however, it can also increase lean mass, though these effects are typically 
modest. BMI only increased from 29.1 to 30.0 kg/m2 in a study of a female-to-male sex reassignment patients 
6 months after initiation of testosterone (31). To minimize the impact of weight influencing our findings, we 
compared the androgen profiles in serum, urine, and CSF to controls matched for BMI. Additionally, we noted 
the absence of a correlation between these measures and BMI in the IIH cohort. Future evaluation of the effects 
of weight loss on androgen profiles and disease activity would be useful to clarify this relationship further.
Using a cell-based model, we have demonstrated the potential for androgens to modify CSF secretion 
in this study. The relative importance of  CSF oversecretion versus CSF underdrainage is debated in the 
literature (18). It is unlikely that dysregulation of  either CSF secretion or drainage occurs in isolation, and 
indeed these processes are likely to influence each other. Our study is limited in that we have not assessed 
the impact of  androgens on CSF drainage.
Current therapeutic strategies for IIH are limited (5), with significant morbidity from visual loss and 
long-term headache. We show that women with IIH have a distinct androgen excess signature, which, with 
the in vitro assay on Na+/K+-ATPase activity, supports a potential role for androgens in the pathogenesis 
of  IIH. We propose that potent androgens are activated in the choroid plexus and/or cross the blood-brain 
barrier after activation in other tissues where they affect CSF secretion and ICP. Therapeutically targeting 
androgen excess in IIH will be an important next step in testing this hypothesis in the clinical setting.
Methods
Detailed descriptions of  experimental procedures are reported in the Supplemental Methods.
Cohorts. Women with IIH aged between 18 and 45 years were recruited from neurology clinics at Uni-
versity Hospital Birmingham, as well as ophthalmology clinics at the Birmingham and Midland Eye Cen-
tre, after they provided written informed consent. IIH patients were diagnosed according to the modified 
Dandy criteria and were included only if  they had active, untreated disease with ongoing papilledema (Fris-
en grade ≥1; ref. 32) and opening CSF pressure greater than 25 cm H2O at the time of  sample collection (1).
Women with PCOS as well as healthy controls were recruited from endocrine outpatient clinics at 
University Hospital Birmingham and Birmingham Women’s Hospital and from local advertising, respec-
tively, with full ethical approval obtained (see Study Approval in main Methods section). A further cohort 
of  healthy control women was recruited from Adelaide and Meath Hospital, Dublin, Ireland. PCOS was 
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diagnosed according to the Rotterdam European Society of  Human Reproduction and Embryology 2004 
criteria (presence of  2 or more of  the following criteria: oligo-anovulation, clinical or biochemical hyperan-
drogenism, and polycystic ovaries on ultrasound).
The female lean control cohort for CSF evaluation consisted of  patients with non-IIH neurological 
disease (after providing written informed consent) and a control cohort with obesity (with no known 
comorbidities) recruited solely for research evaluation through local advertising. Written informed con-
sent was provided in all cases.
Exclusion criteria for the study were recent glucocorticoid therapy (within 3 months), pregnancy, 
recent oral contraceptive or antiandrogen use (within 3 months), hyperprolactinemia, and overt hypergly-
cemia. PCOS was excluded on clinical and biochemical assessment from the control cohorts. The cohorts 
were whole-group matched (for age, sex, and BMI) for comparison unless otherwise stated. Participants 
attended the NIHR/Wellcome Trust Clinical Research Facility at University Hospital Birmingham after 
an overnight fast. Baseline anthropometric data were collected and serum samples were drawn for mea-
surement of  serum androgens. Precollected 24-hour urine samples for urinary steroid metabolite profiling 
were also provided by patients upon arrival to the research facility. In IIH patients, CSF samples were also 
collected by lumbar puncture (LP). CSF and blood samples were transported on ice before being promptly 
centrifuged at 226 x g for 10 minutes and aliquoted. All samples were stored at –80°C and analyzed after a 
maximum of  1 freeze-thaw cycle.
Visual assessments were recorded during the research visit. Best corrected visual acuity was measured 
with a Humphrey Visual Field analyzer using the Swedish Interactive Threshold Algorithm Standard 24-2 
program and mean deviation was recorded. OCT (Heidelberg Spectralis Spectral Domain OCT) was acquired 
to record average and maximal retinal nerve fiber layer thickness. LP was performed after all visual assess-
ments. LP pressure was evaluated with the participant breathing steadily in the lateral position, legs flexed 
90° at the hip, with adequate time taken to ensure a stable reading. Headache disability was recorded using 
the HIT-6 (33). Quality of  life was assessed using the SF-36 Version 1 (RAND 36-Item Short Form Survey).
ATP/ADP CSF secretion assay. CSF secretion occurs predominantly at the choroid plexus epithelial cells; 
numerous ion channels are involved but the Na+/K+-ATPase is a key rate-limiting step in driving CSF secretion 
(34, 35). Specific inhibition of the Na+/K+-ATPase with ouabain reduces CSF secretion by 70% to 80% (35). 
ATP consumed by Na+/K+-ATPase activity is a marker of CSF secretion (20). Na+/K+-ATPase activity was 
measured by determining increases in the ATP/ADP ratio in the presence and absence of ouabain (35). Mea-
sures of the total ATP/ADP could not be used because they reflect multiple cellular processes and are not spe-
cific for Na+/K+-ATPase activity; hence we report only the changes in the ATP/ADP ratio sensitive to ouabain.
Assays were conducted in Z310 cells (courtesy of  Wei Zheng, Purdue University, West Lafayette, Indi-
ana, USA), an immortalized cell line derived from primary rat choroid plexus epithelium transfected by simi-
an virus 40 T antigen (36). Cells were infected 2 days before imaging with adenovirus containing Perceval, an 
ATP/ADP ratio biosensor. The ATP/ADP ratio was imaged using a CrestOptics X-Light spinning disk head 
coupled to a Nikon Ti-E automated base and 10×/0.4× numerical aperture objective. Excitation was deliv-
ered by a Lumencor Spectra X light engine at 458–482 nm (0.2 Hz), and emitted signals were detected with a 
Photometrics Evolve Delta 512 EMCCD at 500–550 nm. The ATP/ADP traces were normalized as F/Fmin, 
where F is the fluorescence at a given time point and Fmin is the minimum fluorescence. Cells were treated 
with either testosterone (100 nM) or acetazolamide (100 mM; positive control) before recording ATP/ADP 
and applying 1 mM ouabain, the increase in Perceval fluorescence reflecting the portion of  ATP consumed by 
Na+/K+-ATPase activity. A HEPES-bicarbonate buffer was used, containing the following in mM: 120 NaCl, 
4.8 KCl, 24 NaHCO3, 0.5 Na2HPO4, 5 HEPES, 2.5 CaCl2, 1.2 MgCl2, and 25 D-glucose.
Analysis of  live cell data. Images were acquired with MetaMorph (Molecular Devices). An image 
sequence was initially analyzed on ImageJ (V1.48; NIH), where individual random cells are selected as a 
region of  interest and motile cells are excluded from the analysis. Following this, the multimeasure func-
tion was selected to determine the mean intensity of  individual cells at each frame. Subsequent to this the 
F/Fmin was determined for each frame, where F is the intensity for the cell in that particular frame and 
Fmin is the lowest fluorescence intensity in the baseline period. This normalizes the change intensity to 
baseline, taking into account any quantitative difference in ATP/ADP ratio between cells or differences 
in Perceval protein expression. We used ouabain administration to initiate a change in ATP/ADP ratio 
or Δ (Supplemental Figure 1). This Δ is the maximum F/Fmin value following ouabain administration 
minus the maximum F/Fmin in the baseline (before ouabain administration).
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Statistics. Statistical analysis was performed using SPSS Statistics (Version 22, IBM, Chicago, Illinois, 
USA). All comparisons were performed using Student’s t test (2-tailed), Mann-Whitney U test, or Krus-
kal-Wallis testing. P values < 0.05 were deemed significant.
Study approval. For procedures involving PCOS and healthy controls, approval was granted by the 
South Birmingham (LREC5835), Edgbaston (12/WM/0206), and Adelaide and Meath Hospital Dublin 
(2006/10/02) Research Ethics Committees. Ethical approval for recruitment of  IIH patients was granted 
by the Dudley (06/Q2702/64), Yorkshire and the Humber–Leeds West (13/YH/0366), and Black Country 
(14/WM/0011) local Research Ethics Committees. Ethical approval for CSF samples from patients with 
neurological disease was granted by Solihull Research Ethics Committee (04/Q2706/65). The Parkinson’s 
UK Brain Bank has ethical approval from the Wales Research Ethics Committee as a research tissue bank, 
which covers the use of  tissue from the Brain Bank by researchers.
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